CAS 183321-74-6

Erlotinib

Description:

Erlotinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It specifically targets the epidermal growth factor receptor (EGFR), which is often overexpressed in various tumors, leading to uncontrolled cell proliferation. Erlotinib is characterized by its ability to inhibit the phosphorylation of EGFR, thereby blocking downstream signaling pathways that promote tumor growth and survival. The compound is typically administered orally and has a relatively high bioavailability. Its chemical structure includes a quinazoline core, which is essential for its activity, and it exhibits a moderate to high affinity for the EGFR tyrosine kinase domain. Common side effects associated with erlotinib treatment include rash, diarrhea, and potential liver enzyme elevation. Due to its mechanism of action, erlotinib is often used in patients with specific EGFR mutations, making it a targeted therapy in oncology. As with all medications, its use should be guided by a healthcare professional, considering the patient's overall health and specific cancer characteristics.

Formula: C₂₂H₂₃N₃O₄

InChI: InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)

InChI key: InChIKey=AAKJLRGGTJKAMG-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=C(OCCOC)C(OCCOC)=C2)N=CN1)C3=CC(C#C)=CC=C3

Synonyms:

• 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-
• 4-[(3-Ethynylphenyl)Amino]-6,7-Bis(2-Methoxyethoxy)Quinazoline
• Erlotinib & its intermediates (Developing)
• Erlotinib Base
• Erlotinin
• N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
• N-(3-Ethynylphenyl)[6,7-Bis(2-Methoxyethoxy)Quinazolin-4-Yl]Amine
• NSC 718781
• Osi 744
• R 1415
• Erlotinib

Erlotinib

CAS: 183321-74-6

Purity: 98%

Molecular weight: 393.44

Ref: 10-F050702

ERLOTINIB HYDROCHLORIDE CRS

CAS: 183321-74-6

ERLOTINIB HYDROCHLORIDE CRS

Ref: 41-Y0002444

Erlotinib

CAS: 183321-74-6

Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Formula: C₂₂H₂₃N₃O₄

Purity: 98.19% - 99.98%

Color and Shape: White To Off-White Powder

Molecular weight: 393.44

Ref: TM-T0373

4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-

CAS: 183321-74-6

Formula: C₂₂H₂₃N₃O₄

Purity: 95%

Color and Shape: Solid

Molecular weight: 393.4357

Ref: IN-DA0027HY

Erlotinib

CAS: 183321-74-6

Formula: C₂₂H₂₃N₃O₄

Purity: ≥ 99.0% (anhydrous basis)

Color and Shape: White to light-yellow powder

Molecular weight: 393.44

Ref: 7W-GP0576

Erlotinib Free Base

CAS: 183321-74-6

Erlotinib Free Base

Formula: C₂₂H₂₃N₃O₄

Purity: By hplc: >99% (Typical Value in Batch COA)

Color and Shape: white solid

Molecular weight: 393.44g/mol

Ref: 54-BIFK0019

N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine

Controlled Product

CAS: 183321-74-6

Applications Erlotinib is a EGFR-targeted drug in the treatment of non-small cell lung cancer. EGFR small tyrosine kinase inhibitor that shows most substantial effect on tumor growth inhibition and animal survival.
References Zhu, B., et al.: Xiandai Zhenduan Yu Zhiliao, 25, 4679 (2014); Yao, T., et al.: Ther. Targets Neurol. Dis., 2, 585 (2015)

Formula: C₂₂H₂₃N₃O₄

Color and Shape: Neat

Molecular weight: 393.44

Ref: TR-E625008

Erlotinib base

CAS: 183321-74-6

Tyrosine kinase inhibitor; affects EGFR receptor; pancreatic cancer treatment

Formula: C₂₂H₂₃N₃O₄

Purity: Min. 99 Area-%

Color and Shape: Powder

Molecular weight: 393.44 g/mol

Ref: 3D-BE164419

Erlotinib

CAS: 183321-74-6

Formula: C₂₂H₂₃N₃O₄

Molecular weight: 393.44

Ref: ST-EA-CP-E17059